References
- Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008;26:77-82
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Diabetes Mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Office of Communications, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed May 1, 2014
- Pelletier EM, Smith PJ, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008;6:103-12
- Straka RJ, Liu LZ, Girase PS, et al. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovasc Diabetol 2009;8:53
- Gandra SR, Lawrence LW, Parasuraman BM, et al. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. J Manag Care Pharm 2006;12:546-54
- Ringborg A, Yin DD, Martinell M, et al. The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil 2009;16:576-82
- Carral F, Aguilar M, Olveira G, et al. Increased hospital expenditures in diabetic patients hospitalized for cardiovascular diseases. J Diabetes Complications 2003;17:331-6
- O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-38
- Ward A, Alvarez P, Vo L, et al. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ 2014;17:176-83
- Truven Health Analytics. MarketScan Bibliography. Ann Arbor, MI: MarketScan, 2015. http://marketscan.truvenhealth.com/marketscanuniversity/publications/2012%20Truven%20Health%20MarketScan%20Bibliography.pdf. Accessed June 20, 2013
- Kapur A, De Palma R. Mortality after myocardial infarction in patients with diabetes mellitus. Heart 2007;93:1504-6
- Collins TC, Petersen NJ, Menke TJ, et al. Short-term, intermediate-term, and long-term mortality in patients hospitalized for stroke. J Clin Epidemiol 2003;56:81-7
- Roumie CL, Mitchel E, Gideon PS, et al. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf 2008;17:20-6
- Metcalfe A, Neudam A, Forde S, et al. Case definitions for acute myocardial infarction in administrative databases and their impact on in-hospital mortality rates. Health Serv Res 2013;48:290-318
- United States Bureau of Labor Statistics. Consumer Price Index Detailed Report Tables Annual Average 2011. Washington, DC: United States Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes, 2011. http://www.bls.gov/cpi/cpid11av.pdf. Accessed May 1, 2014
- Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4:313-20
- Kleinman LC, Norton EC. What’s the risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res 2009;44:288-302